Hemochromatosis clinical trials
The registry lists 55 studies for Hemochromatosis across more than 10 countries. 4 are recruiting or about to start. 37 of them are mainly about Hemochromatosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05.
Get an email when these change. Save the Hemochromatosis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Rennes University Hospital (9) · National Heart, Lung, and Blood Institute (NHLBI) (5) · Novartis Pharmaceuticals (3) · Lipomed (2) · University of Wisconsin, Madison (2) · Sanquin Research & Blood Bank Divisions (2) · Bond Biosciences (2) · St. Jude Children's Research Hospital (2)
What is being tested here
Drugs under test in Hemochromatosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Deferasirox | 0 | 0 | 4 |
| Deferiprone | 0 | 1 | 3 |
| Deferoxamine | 0 | 1 | 3 |
| VIT-2763 | 0 | 0 | 1 |
| Polyphenols | 0 | 0 | 1 |
| Rusfertide | 0 | 0 | 1 |
| Nifedipine | 0 | 0 | 1 |
| Interleukin 1 Receptor Antagonist Protein | 0 | 0 | 1 |
| Hydroxyurea | 0 | 1 | 1 |
| Pantoprazole | 0 | 0 | 1 |
Drug classes tested here Iron chelators 7
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- Dec 2026Treatment of Hemochromatosis · National Institutes of Health Clinical Center (CC)
- Jan 2027Impact of Transferrin Saturation Guided Maintenance Treatment on Quality of Life in HFE Haemochromatosis · Rennes University Hospital
- Feb 2027A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis · Bond Biosciences
Who these studies take
Of the 4 Hemochromatosis studies recruiting now, 2 (50%) set no upper age limit and 2 (50%) stop at 75 or younger. 1 (25%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (50%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (25%) | 1 (25%) |
| 18 | 4 (100%) | 4 (100%) |
| 30 | 4 (100%) | 4 (100%) |
| 40 | 4 (100%) | 4 (100%) |
| 50 | 4 (100%) | 4 (100%) |
| 65 | 4 (100%) | 4 (100%) |
| 75 | 2 (50%) | 2 (50%) |
| 85 | 2 (50%) | 2 (50%) |
Across all 55 studies, recruiting or not: 27% stop at 75 or younger and 16% at 65; 31% take children; 4% are for women only and 5% for men only; 24% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 55. Browse all 55 → or search them.
- A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary HemochromatosisRecruitingNCT07371793Phase 1/21 country
- "Iron Overload and Endocrinological Diseases"RecruitingNCT061370791 country
- An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic SteatosisRecruitingNCT053356031 country
- China Registry for Genetic / Metabolic Liver DiseasesRecruitingNCT031314271 country
- Treatment of HemochromatosisActive, not recruitingNCT00007150Phase 21 country
- Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary HemochromatosisActive, not recruitingNCT07332091Phase 218 countries
- Effects of Polyphenols on Iron Absorption in Iron Overload Disorders.CompletedNCT03453918Not applicable1 country
- Impact of Transferrin Saturation Guided Maintenance Treatment on Quality of Life in HFE HaemochromatosisActive, not recruitingNCT04779593Not applicable1 country
- Bone Status on Patients With Genetic Hemochromatosis: a 3 Years Descriptive and Evolutionary StudyCompletedNCT015563601 country
- Haemochromatosis and PeriodontitisCompletedNCT04006249Not applicable1 country
- Repeatability and Reproducibility of Multiparametric MRICompletedNCT037432722 countries
- PTG-300 in Subjects With Hereditary HemochromatosisCompletedNCT04202965Phase 22 countries
- Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron ContentCompletedNCT020255431 country
- Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)TerminatedNCT03203850Phase 27 countries
- MRI QSM Imaging for Iron OverloadCompletedNCT046317181 country
- Cardiac Function in Patients With Hereditary HemochromatosisCompletedNCT000681591 country
- Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic SyndromeWithdrawnNCT01892644Phase 21 country
- A Study to Evaluate BBI-001 in Hereditary Haemochromatosis (HH) Patients and Iron Deficient VolunteersTerminatedNCT05238207Phase 11 country
- Analysis of the Effect of Iron Supplements on Iron Deficiency Anemia in PregnancyStatus unknownNCT05804071Phase 41 country
- Implications for Quality of Life and Quality of Care in Patients With Hereditary HaemochromatosisWithdrawnNCT019919251 country
- Quality and Biologic Characteristics of Red Blood Concentrates Obtained From Individuals With Elevated Ferritin.Status unknownNCT05742035Not applicable1 country
- A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary HemochromatosisCompletedNCT03395704Phase 24 countries
- Impact of Bloodletting on Iron Metabolism in Type 1 HemochromatosisCompletedNCT01810965Not applicable1 country
- Liver Fibrosis in Sickle Cell DiseaseCompletedNCT020077461 country
- Deferoxamine for the Treatment of HemochromatosisCompletedNCT000012031 country
- Transferrin Saturation and Asthenia in HemochromatosisCompletedNCT033565481 country
- Massive Iron Deposit AssessmentCompletedNCT01572922Not applicable1 country
- Analysis of the Modulation of Serum Hepcidin Level in Response to Iron Oral Intake: Potential Interest for the Differential Diagnosis Between Ferroportin Disease and Dysmetabolic Hepatosiderosis.CompletedNCT01949467Phase 21 country
- Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II StudyTerminatedNCT02263638Phase 21 country
- Research Network for Neonatal Diseases Induced by Tissular Fetomaternal AlloimmunizationCompletedNCT001996281 country
- Study of the Cellular Diffusion of Tacrolimus Across the Membrane of Mononuclear CellsCompletedNCT036547941 country
- Iron Overload in Stem Cell Transplant RecipientsCompletedNCT008067151 country
- Oral Nifedipine to Treat Iron OverloadCompletedNCT00712738Phase 11 country
- Respiratory Variations For Assessing Blood WithdrawalCompletedNCT030664141 country
- Mi-iron - Moderately Increased Iron - is Reducing Iron Overload Necessary?CompletedNCT01631708Not applicable1 country
- Hemochromatosis and Iron Overload Screening Study (HEIRS)CompletedNCT00005541
- Statistical Basis for Hemochromatosis ScreeningCompletedNCT00005559
- Evaluation of a New MR Pulse Sequence to Quantify Liver Iron ConcentrationCompletedNCT005875351 country
- Hemochromatosis--Genetic Prevalence and PenetranceCompletedNCT00006312
- Efficacy Study in Removing Excess Iron From the HeartCompletedNCT00105495Phase 42 countries
- Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron OverloadCompletedNCT00600938Phase 211 countries
- HEPFER-Evaluation of a New Phenotypic Biological Marker in Genetic Type 1 HemochromatosisCompletedNCT017849391 country
- Erythrocytapheresis Versus Phlebotomy as Maintenance Therapy in Hereditary Hemochromatosis (HH) PatientsStatus unknownNCT01398644Phase 31 country
- Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional HemochromatosisCompletedNCT00000595Phase 2
- Stroke With Transfusions Changing to HydroxyureaTerminatedNCT00122980Phase 31 country
- Study With Deferiprone and/or Desferrioxamine in Iron Overloaded PatientsCompletedNCT00350662Phase 32 countries
- Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary HemochromatosisStatus unknownNCT01524757Not applicable2 countries
- Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent PatientsCompletedNCT00349453Phase 21 country
- Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary HemochromatosisCompletedNCT00395629Phase 1/26 countries
- Screening of Hepatocellular Carcinoma in Patients With Compensated CirrhosisCompletedNCT00190385Phase 31 country